Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 135.6% from a year ago
Cash & equivalents stood at $62.44M at the end of Q1 FY2026, up 135.6% from a year earlier and up 32.7% from the prior quarter. Over 3 fiscal years it compounded at +44.6% a year.
Context
- Cash & equivalents amounted to 63.3% of total assets at the end of Q1 FY2026, up 46.5 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +135.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 47.05M USD
- Year-over-year change
- -23.7%
- 3-year CAGR
- +44.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.05M | -23.7% |
| FY2024 | 2024-12-31 | 61.64M | +533.2% |
| FY2023 | 2023-12-31 | 9.74M | -37.4% |
| FY2022 | 2022-12-31 | 15.56M | — |
Cash & Equivalents vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 cash & equivalents of $62.44M is the 4th highest of the 11 companies compared; the peer median is $33.02M.
- Its year-over-year change of +135.6% is the highest of 11, against a peer median of -4.9%.
- Cash & equivalents amounts to 63.3% of total assets for AARD, versus a peer median of 19.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ZURAZura Bio Limited | Mar 2026 | $225.59M | +32.3% | +311.8% | 98.7% |
| Mar 2026 | $88.91M | +45.7% | +15.7% | 40.0% | |
| Mar 2026 | $80.89M | +50.4% | +1.8% | 59.9% | |
| Mar 2026 | $62.44M | +135.6% | +44.6% | 63.3% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $58.69M | +113.8% | +48.2% | 40.2% |
| Mar 2026 | $34.93M | -42.0% | -9.8% | 11.1% | |
| Mar 2026 | $31.12M | +32.9% | +3.7% | 13.2% | |
| Mar 2026 | $24.99M | -80.0% | +6.4% | 25.0% | |
| Mar 2026 | $14.63M | -56.0% | -52.4% | 8.2% | |
| Mar 2026 | $12.06M | -59.0% | -40.4% | 8.1% | |
| Mar 2026 | $7.24M | -43.3% | -55.9% | 11.3% | |
| Peer median (excluding AARD) | $33.02M | -4.9% | +2.8% | 19.1% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.